NASDAQ:TBPH Theravance Biopharma (TBPH) Stock Price, News & Analysis $10.25 +0.04 (+0.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.17▼$10.4250-Day Range$8.29▼$10.2552-Week Range$8.13▼$11.71Volume218,575 shsAverage Volume399,909 shsMarket Capitalization$498.46 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Theravance Biopharma alerts: Email Address Theravance Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Upside$20.50 Price TargetShort InterestBearish12.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 6 Articles This WeekInsider TradingSelling Shares$36,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.42) to $0.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector599th out of 936 stocksPharmaceutical Preparations Industry275th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingTheravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTheravance Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Theravance Biopharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.62% of the float of Theravance Biopharma has been sold short.Short Interest Ratio / Days to CoverTheravance Biopharma has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Theravance Biopharma has recently decreased by 3.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTheravance Biopharma does not currently pay a dividend.Dividend GrowthTheravance Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TBPH. Previous Next 2.9 News and Social Media Coverage News SentimentTheravance Biopharma has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Theravance Biopharma this week, compared to 1 article on an average week.Search Interest1 people have searched for TBPH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,000.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Theravance Biopharma is held by insiders.Percentage Held by Institutions99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Theravance Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Theravance Biopharma are expected to grow in the coming year, from ($0.42) to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Theravance Biopharma is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theravance Biopharma is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheravance Biopharma has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Theravance Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Theravance Biopharma Stock (NASDAQ:TBPH)Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Read More TBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TBPH Stock News HeadlinesJuly 13, 2024 | insidertrades.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells $36,000.00 in StockJuly 25 at 6:00 AM | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceJuly 27, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 25 at 5:34 AM | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Downgraded by StockNews.com to "Hold"July 24 at 10:32 AM | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH): When Will It Breakeven?July 22, 2024 | prnewswire.comTheravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024May 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)May 21, 2024 | finance.yahoo.comTheravance Biopharma First Quarter 2024 Earnings: Beats ExpectationsJuly 27, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline ProspectsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug ProspectsMay 14, 2024 | msn.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call TranscriptMay 13, 2024 | investorplace.comTBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.24 beats by $0.01, revenue of $14.51M beats by $0.56MMay 13, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | markets.businessinsider.comTheravance Biopharma earnings preview: what Wall Street is expectingMay 12, 2024 | msn.comTheravance Biopharma Q1 2024 Earnings PreviewMay 9, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceSee More Headlines Receive TBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A CIK1583107 Webwww.theravance.com Phone(650) 808-6000FaxN/AEmployees359Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$21.00 Low Stock Price Target$20.00 Potential Upside/Downside+100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,190,000.00 Net Margins-72.79% Pretax Margin-60.46% Return on Equity-18.97% Return on Assets-11.10% Debt Debt-to-Equity RatioN/A Current Ratio5.74 Quick Ratio5.74 Sales & Book Value Annual Sales$57.42 million Price / Sales8.68 Cash FlowN/A Price / Cash FlowN/A Book Value$4.28 per share Price / Book2.39Miscellaneous Outstanding Shares48,630,000Free Float45,277,000Market Cap$498.46 million OptionableOptionable Beta0.25 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesRick E. WinninghamChairman & Chief Executive OfficerAndrew Asa HindmanChief Financial Officer & Senior Vice PresidentVijay SabesanSenior Vice President-Technical OperationsPhilip D. WorboysSenior VP-Research & Translational ScienceBradford J. ShaferSecretary, Executive VP & General CounselKey CompetitorsAnnexonNASDAQ:ANNXPliant TherapeuticsNASDAQ:PLRXZai LabNASDAQ:ZLABAkero TherapeuticsNASDAQ:AKROVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 11,056 shares on 7/26/2024Ownership: 0.310%SG Americas Securities LLCSold 47,178 shares on 7/12/2024Ownership: 0.334%Rhonda FarnumSold 4,000 sharesTotal: $36,000.00 ($9.00/share)Jacobs Levy Equity Management Inc.Bought 163,951 shares on 5/16/2024Ownership: 1.149%California State Teachers Retirement SystemSold 7,930 shares on 5/16/2024Ownership: 0.079%View All Insider TransactionsView All Institutional Transactions TBPH Stock Analysis - Frequently Asked Questions How have TBPH shares performed this year? Theravance Biopharma's stock was trading at $11.24 at the beginning of the year. Since then, TBPH stock has decreased by 8.8% and is now trading at $10.25. View the best growth stocks for 2024 here. How were Theravance Biopharma's earnings last quarter? Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Monday, May, 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The biopharmaceutical company earned $14.50 million during the quarter, compared to analysts' expectations of $14.54 million. Theravance Biopharma had a negative net margin of 72.79% and a negative trailing twelve-month return on equity of 18.97%. Who are Theravance Biopharma's major shareholders? Theravance Biopharma's top institutional shareholders include SG Americas Securities LLC (0.33%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Richard A Graham and Rhonda Farnum. View institutional ownership trends. How do I buy shares of Theravance Biopharma? Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Theravance Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ) and Merck & Co., Inc. (MRK). This page (NASDAQ:TBPH) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
